CYDYCytoDyn Inc.

About CytoDyn Inc. (CYDY)

CytoDyn Inc. (CYDY) is a Biotechnology company headquartered in Vancouver, WA, United States whose shares trade over-the-counter on the OTCQB tier.

CytoDyn Inc. (together with its wholly owned subsidiaries, the "Company") was originally incorporated under the laws of Colorado on May 2, 2002, under the name RexRay Corporation and, effective August 27, 2015, reincorporated under the laws of Delaware. The Company is a clinical-stage biotechnology company focused on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 ("CCR5").

Products and services

CytoDyn Inc. is a clinical stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Leronlimab is being studied for oncology and inflammation, as well as other potential indications.

CYDY key facts

Ticker symbol

CYDY

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Vancouver, WA, United States

Country of incorporation

US

Employees

12

Estimated market cap

$282.23M (as of Apr 9, 2025)

Shares outstanding

1,232,432,862

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

5/31

CytoDyn Inc. leadership

• Jacob P. Lalezari, M.D. — CEO, Principal Executive Officer
• Mitchell Cohen — Interim CFO, Principal Acct. Officer, Principal Fin. Officer
• Tyler Blok — Corporate Secretary, Chief Legal Officer

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with C